Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer
Experts highlight the risk factors, comorbidities, diagnosis, economic burden, and treatments for brain metastasis in metastatic breast cancer based on data presented at the 2020 San Antonio Breast Cancer Symposium.
PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma
At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma
Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma
Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512